Breaking Now: (RNAZ) Moves Approx. 22% After Fresh Clinical Milestone Confirmed

*Sponsored Market Crux Announces Its Next Potential Breakout Idea For  This Morning—Thursday, May 1, 2025  TransCode Therapeutics (Nasdaq: RNAZ) Just Hit Our Radar! Here’s Why… (RNAZ) Recently Moved Approximately 93% Inside Of Nine Sessions, From $0.2196 To $0.425 While Breaking Key Moving Averages. (RNAZ) Float is Listed as Under 21M Shares—Which Could Set The Stage For Big Swing Potential If Demand Begins To Shift.  Analyst Target From HC Wainwright Set At $10 For (RNAZ), Reported By Benzinga, Suggests Over 2,250% Upside Potential. Get (RNAZ) On Your Screen While It’s Still Early… May 1, 2025 Dear Reader, A major clinical update hit the wires this morning—and TransCode Therapeutics (Nasdaq: RNAZ) is quickly becoming the biotech name to watch today. Benzinga just reported that 13 patients have now been dosed in the company’s Phase 1 trial, with zero dose-limiting toxicities reported. Two patients remain on therapy after seven months, showing stable disease—a key signal in metastatic cancer. Even more compelling: early data shows the therapy is doing what it was built to do—targeting the cancer-driving miRNA-10b pathway in humans.  Add in the FDA’s Orphan Designation for pancreatic cancer, and the foundation is now in place for the next phase of clinical momentum. In the early session, (RNAZ) moved approximately 22%, reaching $0.497 from yesterday’s close of $0.4066.  We’re tracking the chart and the story closely as this continues to unfold. This one’s been quietly building in the background—just another early-stage player in a crowded space dominated by legacy names and immune-first approaches. But that’s no longer the case. What started as a bold concept—targeting the genetic drivers of metastatic cancer with custom-built RNA therapeutics—is now producing real, measurable signals in humans. Their lead compound isn’t just in a Phase 1 trial—it’s reaching tumors in the liver, lungs, and bones, confirmed in clinical imaging.  Even at low doses, it’s generating target-specific responses in blood samples. This isn’t hypothetical anymore—it’s happening inside real patients. And people are starting to notice. Just weeks ago, Benzinga reported that HC Wainwright & Co.—one of the country’s oldest institutions—set their target on (RNAZ) at $10. That suggests a potential upside of more than 2,300% from yesterday’s $0.4066 close. That $10 target didn’t come out of nowhere. Over the past 9 sessions alone, (RNAZ) has quietly moved approximately 93%, from $0.2196 on April 17 to $0.425 yesterday (April 30, 2025)—pushing above its 5- and 20-day moving averages. With its 50-day moving average still way up at $1.5253, we have all eyes on (RNAZ) right now. But keep in mind, (RNAZ) has less than 21M shares in its float—which could set the stage for potential swings if demand begins to shift. Keep reading to see why (RNAZ) is topping our watchlist this morning… (RNAZ) Therapy Reaches Cancer Sites in Human Study One of the most compelling reasons (RNAZ) is on watch right now is that their science is already in humans—and showing activity.  Their lead therapeutic, TTX-MC138, is currently in a Phase 1a trial, but what truly sets this program apart is what’s already been observed in a prior Phase 0 microdose study.  The compound didn’t just circulate—it reached metastatic lesions in the liver, lungs, and bones of a real human patient.   Even at subtherapeutic doses, it triggered measurable pharmacodynamic activity in blood samples, offering early validation that the therapy is targeting cancer-driving microRNA inside the body. And that early signal is exactly what researchers want to see before doubling down. With real evidence of tumor engagement already in hand, the next question became: would regulators see the same potential? FDA Grants Orphan Status as (RNAZ) Expands Its RNA Platform... Adding to the momentum, the FDA has granted Orphan Designation for pancreatic cancer, one of the deadliest and most challenging types to treat.  This signals a strong degree of regulatory alignment and highlights the clinical significance of their target, miRNA-10b, which has been closely linked to the spread and progression of multiple aggressive cancers. But this isn’t a single-shot pipeline.  TransCode Therapeutics (Nasdaq: RNAZ)’s delivery system has broad potential across multiple RNA modalities, capable of transporting siRNA, antisense oligos, and immunostimulatory payloads with high precision.  The company is already expanding the platform with new candidates—TTX-siPDL1, a checkpoint inhibitor designed to improve immune engagement, and TTX-RIGA, which aims to activate the body’s innate immune response to help eliminate tumors from within. In Preclinical Models—Complete Regressions… Backing this clinical ambition is animal data that’s hard to overlook. In both murine models and spontaneous feline cancers, TTX-MC138 has delivered complete regressions of metastatic disease and extended survival significantly—even in late-stage cases.  These results speak to the potential power of the platform when it translates from lab to clinic. One Platform. Multiple Targets. (RNAZ) Quietly Builds a Therapeutic Arsenal… On March 27, 2025, TransCode announced that it had initiated dosing in its fourth cohort of the ongoing Phase 1 trial for TTX-MC138. This marks a key step forward in the program, with ten patients now treated at escalating dose levels.  The company’s ability to progress this trial without interruption adds meaningful weight to its early-stage development and reinforces that momentum is not just theoretical—it’s being measured one patient at a time. Now that they’ve proven the delivery system can reach the hardest-to-hit areas—metastatic sites—the company is rolling out new candidates using the same backbone. Their siRNA-based checkpoint inhibitor (TTX-siPDL1) has already shown potential to regress pancreatic tumors by ~90% in animal models when combined with chemo. Another, TTX-RIGA, is being positioned as an immune trigger with possible impact across recurrent or deep-tissue tumors. The pipeline is no longer just one bullet.  It’s a modular platform—one with the potential to address multiple angles of cancer treatment using custom-built RNA tools. And right now, that platform is finally stepping out of the shadows and into the spotlight. With key milestones stacking up—and the clinical picture coming into sharper focus—there’s real reason to be paying attention. 7 Reasons Why TransCode Therapeutics (Nasdaq: RNAZ) is Topping Our Watchlist—This Morning—Thursday, May 1, 2025… 1. Limited Float: With a float reportedly under 21M shares and over $62M raised without excessive dilution, (RNAZ) stands out structurally. That combination—fiscal runway with a tight share count—can often be a potential catalyst if demand begins to shift. 2. Analyst Target: HC Wainwright & Co., one of the longest-standing names on the street, recently set their target on (RNAZ) at $10, as reported by Benzinga. That figure suggests over 2,250% upside potential. 3. Recent Market Recognition: In just the last 9 sessions, (RNAZ) moved approximately 93%, from $0.2196 on April 17 to $0.425 by April 30, 2025. That kind of move—especially while surpassing its 5 and 20-day moving averages—can signal growing interest and the potential for continued momentum. 4. Early Human Data Confirms Tumor Targeting: Their lead RNA-based therapeutic, TTX-MC138, has already been evaluated in a human Phase 0 study. Imaging showed the compound reached metastatic lesions in the liver, lung, and bone, and lab results showed significant target activity—demonstrated even at low doses. 5. Tumors Disappeared in Preclinical Trials: In preclinical studies, TTX-MC138 delivered more than just a slowdown—it triggered complete regressions in advanced metastatic cancer models.  6. FDA Greenlights Program: The FDA granted Orphan Designation for TTX-MC138 in pancreatic cancer—a notoriously difficult disease. This designation supports the seriousness of the science and indicates alignment with regulators focused on unmet needs. 7. The Pipeline Is Stacking Up: (RNAZ) isn’t limited to one candidate. Their delivery platform supports a variety of payloads including siRNA, antisense, and immune activators. Two new candidates—TTX-siPDL1 and TTX-RIGA—are already in development, extending the reach of the platform across multiple targets and tumor types. Get (RNAZ) On Your Screen While It’s Still Early… As momentum builds around RNA-focused therapeutics, TransCode Therapeutics (Nasdaq: RNAZ) is stepping into a category of its own.  An approximate 93% move in just 9sessions. A $10 target from one of the country’s oldest firms. And a float under 21M shares backed by more than $62Min funding.  That’s not hype—that’s structure. Add in real human data confirming tumor targeting, an FDA Orphan Designation, and complete tumor regression in preclinical models—and suddenly this isn’t just early-stage potential.  It’s a little-known company catching attention for the right reasons. (RNAZ) has the hallmarks of a profile that can shift quickly if interest builds.  And with multiple candidates now advancing from the same modular platform, this could be the start of something much bigger. (RNAZ) is already at the top of our screens—we cannot wait for the opening bell to ring. Take a quick look at (RNAZ) while it’s still early. (RNAZ) moved approximately 22%, reaching $0.497 from yesterday’s close of $0.4066. Are you watching this yet?  Keep in mind—my next update could be out at any moment. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. *Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 04/30/2025 and ending on 05/01/2025 to publicly disseminate information about (RNAZ:US) via digital communications. Under this agreement, Headline Media LLC has been paid seven thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Headline Media LLC, TD Media LLC and their member own shares of (RNAZ:US). Please see important disclosure information here: https://marketcrux.com/disclosure/rnaz-8m3bh/#details

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice